|
US9163087B2
(en)
*
|
2010-06-18 |
2015-10-20 |
The Brigham And Women's Hospital, Inc. |
Bi-specific antibodies against TIM-3 and PD-1 for immunotherapy in chronic immune conditions
|
|
DK2734205T3
(en)
|
2011-07-21 |
2018-06-14 |
Tolero Pharmaceuticals Inc |
Heterocyclic Protein Kinase Inhibitors
|
|
US12466897B2
(en)
|
2011-10-10 |
2025-11-11 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
|
WO2013090552A1
(en)
*
|
2011-12-13 |
2013-06-20 |
Yale University |
Compositions and methods for reducing ctl exhaustion
|
|
KR102069397B1
(ko)
|
2012-02-15 |
2020-01-22 |
에프. 호프만-라 로슈 아게 |
Ｆｃ-수용체 기재 친화성 크로마토그래피
|
|
EP2817327A1
(en)
*
|
2012-02-21 |
2014-12-31 |
Institut National de la Sante et de la Recherche Medicale (INSERM) |
Tim receptors as virus entry cofactors
|
|
EP2817619B1
(en)
*
|
2012-02-23 |
2018-07-25 |
Sloan Kettering Institute For Cancer Research |
Prediction of responsiveness to treatment with immunomodulatory therapeutics and method of monitoring abscopal effects during such treatment
|
|
CA2876689C
(en)
|
2012-06-13 |
2022-04-26 |
Incyte Corporation |
Substituted tricyclic compounds as fgfr inhibitors
|
|
JP2015525781A
(ja)
*
|
2012-07-31 |
2015-09-07 |
ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． |
免疫応答の調節
|
|
EA201590451A1
(ru)
|
2012-08-30 |
2016-05-31 |
Эмджен Инк. |
Способ лечения меланомы с применением вируса простого герпеса и ингибитора иммунной контрольной точки
|
|
US11053316B2
(en)
|
2013-01-14 |
2021-07-06 |
Xencor, Inc. |
Optimized antibody variable regions
|
|
US10968276B2
(en)
|
2013-03-12 |
2021-04-06 |
Xencor, Inc. |
Optimized anti-CD3 variable regions
|
|
US9605084B2
(en)
|
2013-03-15 |
2017-03-28 |
Xencor, Inc. |
Heterodimeric proteins
|
|
KR102391731B1
(ko)
|
2013-01-14 |
2022-04-27 |
젠코어 인코포레이티드 |
신규한 이형이량체 단백질
|
|
US10487155B2
(en)
|
2013-01-14 |
2019-11-26 |
Xencor, Inc. |
Heterodimeric proteins
|
|
EP2948475A2
(en)
*
|
2013-01-23 |
2015-12-02 |
AbbVie Inc. |
Methods and compositions for modulating an immune response
|
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
|
EP2986306A4
(en)
|
2013-04-18 |
2016-12-07 |
Armo Biosciences Inc |
METHOD FOR USE OF INTERLEUKIN-10 FOR THE TREATMENT OF ILLNESSES AND SUFFERING
|
|
PH12015502383B1
(en)
|
2013-04-19 |
2023-02-03 |
Incyte Holdings Corp |
Bicyclic heterocycles as fgfr inhibitors
|
|
RS61400B1
(sr)
|
2013-05-02 |
2021-02-26 |
Anaptysbio Inc |
Antitela usmerena protiv programirane smrti-1 (pd-1)
|
|
CA2914837A1
(en)
|
2013-06-17 |
2014-12-24 |
Armo Biosciences, Inc. |
Method for assessing protein identity and stability
|
|
AR097306A1
(es)
|
2013-08-20 |
2016-03-02 |
Merck Sharp & Dohme |
Modulación de la inmunidad tumoral
|
|
US10010588B2
(en)
|
2013-08-30 |
2018-07-03 |
Armo Biosciences, Inc. |
Methods of using pegylated interleukin-10 for treating hyperlipidemia
|
|
EP3049442A4
(en)
*
|
2013-09-26 |
2017-06-28 |
Costim Pharmaceuticals Inc. |
Methods for treating hematologic cancers
|
|
KR20160079114A
(ko)
|
2013-11-11 |
2016-07-05 |
아르모 바이오사이언시스 인코포레이티드 |
질환 및 장애를 치료하기 위한 인터류킨-10을 사용하는 방법
|
|
CR20160319A
(es)
|
2013-12-12 |
2016-11-08 |
Jiangsu Hengrui Medicine Co |
Anticuerpo pd-1, fragmento de union al antigeno de este y uso médico de este
|
|
ES2918501T3
(es)
|
2013-12-19 |
2022-07-18 |
Novartis Ag |
Receptores de antígenos quiméricos de mesotelina humana y usos de los mismos
|
|
CN103721255A
(zh)
*
|
2014-01-07 |
2014-04-16 |
苏州大学 |
共同阻断pd-1和tim-3信号通路在抗胃癌治疗中的用途
|
|
WO2015112534A2
(en)
*
|
2014-01-21 |
2015-07-30 |
Medimmune, Llc |
Compositions and methods for modulating and redirecting immune responses
|
|
TWI680138B
(zh)
|
2014-01-23 |
2019-12-21 |
美商再生元醫藥公司 |
抗ｐｄ-ｌ１之人類抗體
|
|
TWI681969B
(zh)
|
2014-01-23 |
2020-01-11 |
美商再生元醫藥公司 |
針對ｐｄ-１的人類抗體
|
|
UA122479C2
(uk)
|
2014-01-24 |
2020-11-25 |
Дана-Фарбер Кенсер Інстітьют, Інк. |
Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1)
|
|
PL3099717T3
(pl)
|
2014-01-31 |
2019-10-31 |
Novartis Ag |
Cząsteczki przeciwciała dla TIM-3 i ich zastosowanie
|
|
EA201691765A1
(ru)
|
2014-03-14 |
2016-12-30 |
Новартис Аг |
Молекулы антител против lag-3 и их применения
|
|
CN122399016A
(zh)
|
2014-03-15 |
2026-07-17 |
诺华股份有限公司 |
使用嵌合抗原受体治疗癌症
|
|
SG10202109752XA
(en)
|
2014-04-07 |
2021-10-28 |
Novartis Ag |
Treatment of cancer using anti-cd19 chimeric antigen receptor
|
|
TWI693232B
(zh)
|
2014-06-26 |
2020-05-11 |
美商宏觀基因股份有限公司 |
與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
|
|
WO2016007513A1
(en)
*
|
2014-07-07 |
2016-01-14 |
Dana-Farber Cancer Institute, Inc. |
Methods of treating cancer
|
|
JP2017528433A
(ja)
|
2014-07-21 |
2017-09-28 |
ノバルティス アーゲー |
低い免疫増強用量のｍＴＯＲ阻害剤とＣＡＲの組み合わせ
|
|
WO2016014553A1
(en)
|
2014-07-21 |
2016-01-28 |
Novartis Ag |
Sortase synthesized chimeric antigen receptors
|
|
JP6831777B2
(ja)
|
2014-07-21 |
2021-02-17 |
ノバルティス アーゲー |
Ｃｄ３３キメラ抗原受容体を使用する癌の処置
|
|
WO2016019300A1
(en)
|
2014-07-31 |
2016-02-04 |
Novartis Ag |
Subset-optimized chimeric antigen receptor-containing t-cells
|
|
US9982052B2
(en)
|
2014-08-05 |
2018-05-29 |
MabQuest, SA |
Immunological reagents
|
|
PT3177644T
(pt)
|
2014-08-05 |
2021-01-13 |
MabQuest SA |
Reagentes imunológicos que se ligam a pd-1
|
|
EP3180359A1
(en)
|
2014-08-14 |
2017-06-21 |
Novartis AG |
Treatment of cancer using gfr alpha-4 chimeric antigen receptor
|
|
EP3712171A1
(en)
|
2014-08-19 |
2020-09-23 |
Novartis AG |
Treatment of cancer using a cd123 chimeric antigen receptor
|
|
EP3191126B1
(en)
*
|
2014-09-13 |
2020-05-13 |
Novartis AG |
Combination therapies of alk inhibitors
|
|
US10577417B2
(en)
|
2014-09-17 |
2020-03-03 |
Novartis Ag |
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
|
|
AU2015330898B2
(en)
|
2014-10-08 |
2022-03-10 |
Novartis Ag |
Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof
|
|
CA2964155A1
(en)
|
2014-10-10 |
2016-04-14 |
Idera Pharmaceuticals, Inc. |
Treatment of cancer using tlr9 agonist with checkpoint inhibitors
|
|
SG11201702401RA
(en)
|
2014-10-14 |
2017-04-27 |
Novartis Ag |
Antibody molecules to pd-l1 and uses thereof
|
|
US10927410B2
(en)
|
2014-10-17 |
2021-02-23 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for identification, assessment, prevention, and treatment of T-cell exhaustion using CD39 biomarkers and modulators
|
|
GB201419094D0
(en)
|
2014-10-27 |
2014-12-10 |
Agency Science Tech & Res |
Anti-TIM-3-antibodies
|
|
AU2015340056A1
(en)
|
2014-10-27 |
2017-05-25 |
Agency For Science, Technology And Research |
Anti-TIM-3 antibodies
|
|
GB201419084D0
(en)
|
2014-10-27 |
2014-12-10 |
Agency Science Tech & Res |
Anti-PD-1 antibodies
|
|
PT3215528T
(pt)
|
2014-11-06 |
2019-10-11 |
Hoffmann La Roche |
Variantes da região fc com ligação modificada ao fcrn e métodos de utilização
|
|
SG11201704056XA
(en)
|
2014-11-20 |
2017-06-29 |
Hoffmann La Roche |
Combination therapy of t cell activating bispecific antigen binding molecules cd3 abd folate receptor 1 (folr1) and pd-1 axis binding antagonists
|
|
CN107106608B
(zh)
|
2014-11-20 |
2022-01-21 |
普洛麦格公司 |
用于评估免疫检查点调节剂的系统和方法
|
|
HK1245171A1
(zh)
|
2014-11-26 |
2018-08-24 |
Xencor, Inc. |
结合cd3和cd38的异二聚体抗体
|
|
JP6696982B2
(ja)
|
2014-11-26 |
2020-05-20 |
ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． |
Ｃｄ３および腫瘍抗原に結合するヘテロ二量体抗体
|
|
US10259887B2
(en)
|
2014-11-26 |
2019-04-16 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
|
US20180334490A1
(en)
|
2014-12-03 |
2018-11-22 |
Qilong H. Wu |
Methods for b cell preconditioning in car therapy
|
|
US20170360857A1
(en)
|
2014-12-18 |
2017-12-21 |
Amgen Inc. |
Stable Frozen Virus Formulation
|
|
US10428155B2
(en)
|
2014-12-22 |
2019-10-01 |
Xencor, Inc. |
Trispecific antibodies
|
|
WO2016123573A1
(en)
|
2015-01-30 |
2016-08-04 |
President And Fellows Of Harvard College |
Peritumoral and intratumoral materials for cancer therapy
|
|
WO2016126608A1
(en)
|
2015-02-02 |
2016-08-11 |
Novartis Ag |
Car-expressing cells against multiple tumor antigens and uses thereof
|
|
MA41551A
(fr)
|
2015-02-20 |
2017-12-26 |
Incyte Corp |
Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
|
|
CA2976790C
(en)
|
2015-02-20 |
2024-02-27 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
AU2016229189A1
(en)
*
|
2015-03-06 |
2017-09-21 |
Sorrento Therapeutics, Inc. |
Antibody therapeutics that bind TIM3
|
|
PL3277321T3
(pl)
*
|
2015-04-01 |
2024-11-18 |
Anaptysbio, Inc. |
Przeciwciała skierowane przeciwko białku 3 immunoglobuliny limfocytów t i mucyny (tim-3)
|
|
US20180140602A1
(en)
|
2015-04-07 |
2018-05-24 |
Novartis Ag |
Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives
|
|
US11215616B2
(en)
|
2015-04-10 |
2022-01-04 |
National Institutes Of Health (Nih), (Dhhs), U.S. Government |
Methods of determining patient populations amenable to immunomodulatory treatment of cancer
|
|
WO2016168595A1
(en)
|
2015-04-17 |
2016-10-20 |
Barrett David Maxwell |
Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
|
|
WO2016172583A1
(en)
|
2015-04-23 |
2016-10-27 |
Novartis Ag |
Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
|
|
WO2016171722A1
(en)
*
|
2015-04-24 |
2016-10-27 |
The Brigham And Women's Hospital, Inc. |
Interactions between ceacam and tim family members
|
|
HUE045585T2
(hu)
|
2015-05-18 |
2020-01-28 |
Tolero Pharmaceuticals Inc |
Megnövelt biológiai hozzáférhetõséggel rendelkezõ Alvocidib gyógyszer-elõanyagok
|
|
WO2016191587A1
(en)
|
2015-05-28 |
2016-12-01 |
Armo Biosciences, Inc. |
Pegylated interleukin-10 for use in treating cancer
|
|
TWI773646B
(zh)
|
2015-06-08 |
2022-08-11 |
美商宏觀基因股份有限公司 |
結合lag-3的分子和其使用方法
|
|
TWI870335B
(zh)
*
|
2015-06-12 |
2025-01-21 |
美商宏觀基因股份有限公司 |
變異的嵌合4d5抗體及其與抗pd-1抗體聯合用於治療癌症的應用
|
|
KR20180023968A
(ko)
|
2015-07-02 |
2018-03-07 |
셀진 코포레이션 |
혈액암 및 충실성 종양의 치료를 위한 병용 요법
|
|
MX383464B
(es)
|
2015-07-13 |
2025-03-14 |
Cytomx Therapeutics Inc |
Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y métodos de uso de los mismos.
|
|
MX2017016844A
(es)
|
2015-07-16 |
2018-08-15 |
Biokine Therapeutics Ltd |
Composiciones y procedimientos para tratar cancer.
|
|
US10829735B2
(en)
|
2015-07-21 |
2020-11-10 |
The Trustees Of The University Of Pennsylvania |
Methods for improving the efficacy and expansion of immune cells
|
|
US20180340025A1
(en)
|
2015-07-29 |
2018-11-29 |
Novartis Ag |
Combination therapies comprising antibody molecules to lag-3
|
|
PE20231958A1
(es)
|
2015-07-30 |
2023-12-06 |
Macrogenics Inc |
Moleculas de union a pd-1 y metodos de uso de las mismas
|
|
JO3620B1
(ar)
*
|
2015-08-05 |
2020-08-27 |
Amgen Res Munich Gmbh |
مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم
|
|
EP3337826A1
(en)
|
2015-08-20 |
2018-06-27 |
Sutro Biopharma, Inc. |
Anti-tim-3 antibodies, compositions comprising anti-tim-3 antibodies and methods of making and using anti-tim-3 antibodies
|
|
CA2995120A1
(en)
|
2015-08-25 |
2017-03-02 |
Armo Biosciences, Inc. |
Methods of using interleukin-10 for treating diseases and disorders
|
|
US11385231B2
(en)
|
2015-08-27 |
2022-07-12 |
Inserm (Institut National De La Sante Et De La Recherche Scientifique) |
Methods for predicting the survival time of patients suffering from a lung cancer
|
|
JP6869987B2
(ja)
|
2015-09-01 |
2021-05-12 |
アジェナス インコーポレイテッド |
抗ｐｄ−１抗体及びその使用方法
|
|
WO2017040930A2
(en)
|
2015-09-03 |
2017-03-09 |
The Trustees Of The University Of Pennsylvania |
Biomarkers predictive of cytokine release syndrome
|
|
WO2017055321A1
(en)
|
2015-09-29 |
2017-04-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for quantifying the population of fibroblasts in a tissue sample
|
|
WO2017055320A1
(en)
|
2015-09-29 |
2017-04-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for quantifying the population of cytotoxic lymphocytes in a tissue sample
|
|
WO2017055326A1
(en)
|
2015-09-29 |
2017-04-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for quantifying the population of myeloid dendritic cells in a tissue sample
|
|
WO2017055325A1
(en)
|
2015-09-29 |
2017-04-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for quantifying the population of nk cells in a tissue sample
|
|
WO2017055319A1
(en)
|
2015-09-29 |
2017-04-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for quantifying the population of b cells in a tissue sample
|
|
WO2017055324A1
(en)
|
2015-09-29 |
2017-04-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for quantifying the population of cells of monocytic origin in a tissue sample
|
|
WO2017055327A1
(en)
|
2015-09-29 |
2017-04-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for quantifying the population of endothelial cells in a tissue sample
|
|
WO2017055322A1
(en)
|
2015-09-29 |
2017-04-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for quantifying the population of neutrophils in a tissue sample
|
|
ES2900482T3
(es)
|
2015-10-01 |
2022-03-17 |
Gilead Sciences Inc |
Combinación de un inhibidor de Btk y un inhibidor de punto de control para el tratamiento del cáncer
|
|
WO2017055393A1
(en)
*
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Anti-cd3xtim-3 bispecific t cell activating antigen binding molecules
|
|
PL3368572T5
(pl)
|
2015-10-02 |
2026-07-20 |
Les Laboratoires Servier |
Przeciwciała anty-PD-1 oraz kompozycje
|
|
MA43028B1
(fr)
|
2015-10-02 |
2021-09-30 |
Hoffmann La Roche |
Anticorps bispécifiques pour pd1 et tim3
|
|
US12030942B2
(en)
|
2015-10-02 |
2024-07-09 |
Les Laboratoires Servier |
Anti-PD-1 antibodies and compositions
|
|
WO2017060397A1
(en)
|
2015-10-09 |
2017-04-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting the survival time of subjects suffering from melanoma metastases
|
|
WO2017066561A2
(en)
*
|
2015-10-16 |
2017-04-20 |
President And Fellows Of Harvard College |
Regulatory t cell pd-1 modulation for regulating t cell effector immune responses
|
|
PT3370768T
(pt)
*
|
2015-11-03 |
2022-04-21 |
Janssen Biotech Inc |
Anticorpos que se ligam especificamente ao pd-1 e seus usos
|
|
EP3387013B1
(en)
|
2015-12-07 |
2022-06-08 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and psma
|
|
CN108367069B
(zh)
|
2015-12-14 |
2022-08-23 |
宏观基因有限公司 |
对于pd-1和ctla-4具有免疫反应性的双特异性分子及其使用方法
|
|
CN108495651A
(zh)
|
2015-12-17 |
2018-09-04 |
诺华股份有限公司 |
抗pd-1的抗体分子及其用途
|
|
ES2916874T3
(es)
|
2015-12-17 |
2022-07-06 |
Incyte Corp |
Derivados de N-fenil-piridina-2-carboxamida y su uso como moduladores de la interacción proteína/proteína PD-1/PD-L1
|
|
EP3389720A1
(en)
|
2015-12-18 |
2018-10-24 |
The General Hospital Corporation |
Polyacetal polymers, conjugates, particles and uses thereof
|
|
ES2954153T3
(es)
|
2015-12-22 |
2023-11-20 |
Regeneron Pharma |
Combinación de anticuerpos anti-PD-1 y anticuerpos biespecíficos anti-CD20/anti-CD3 para tratar el cáncer
|
|
CA3009474A1
(en)
|
2015-12-22 |
2017-06-29 |
Incyte Corporation |
Heterocyclic compounds as immunomodulators
|
|
PT3393504T
(pt)
|
2015-12-22 |
2025-12-30 |
Novartis Ag |
Recetor de antigénio quimérico (car) de mesotelina e anticorpo contra o inibidor de pd-l1 para utilização combinada em terapia anticancerígena
|
|
WO2017118634A1
(en)
|
2016-01-04 |
2017-07-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of pd-1 and tim-3 as a measure for cd8+ cells in predicting and treating renal cell carcinoma
|
|
US10052315B2
(en)
|
2016-01-08 |
2018-08-21 |
Celgene Corporation |
Formulations of 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide
|
|
TWI782395B
(zh)
|
2016-01-08 |
2022-11-01 |
美商西建公司 |
抗增生化合物，及其醫藥組合物及用途
|
|
CA3010794A1
(en)
|
2016-01-08 |
2017-07-13 |
Celgene Corporation |
Solid forms of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide, and their pharmaceutical compositions and uses
|
|
PL3964529T3
(pl)
|
2016-01-22 |
2025-10-27 |
MabQuest SA |
Nieblokujące przeciwciała specyficzne względem pd1
|
|
US11214617B2
(en)
|
2016-01-22 |
2022-01-04 |
MabQuest SA |
Immunological reagents
|
|
WO2017129763A1
(en)
|
2016-01-28 |
2017-08-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of signet ring cell gastric cancer
|
|
JP6902040B2
(ja)
|
2016-01-28 |
2021-07-14 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
免疫チェックポイント阻害剤の効力を増強する方法
|
|
JP6970099B2
(ja)
*
|
2016-01-28 |
2021-11-24 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
ガンの処置のための方法及び医薬組成物
|
|
CA3013333A1
(en)
|
2016-02-26 |
2017-08-31 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Antibodies having specificity for btla and uses thereof
|
|
SG11201807489PA
(en)
|
2016-03-04 |
2018-09-27 |
Novartis Ag |
Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
|
|
BR112018068461A2
(pt)
|
2016-03-15 |
2019-01-22 |
Mersana Therapeutics Inc |
conjugado, composição farmacêutica, métodos para preparação de um conjugado e para alívio de um sintoma de um câncer.
|
|
US11564929B2
(en)
|
2016-04-12 |
2023-01-31 |
Eli Lilly And Company |
Combination therapy with Notch and PI3K/mTOR inhibitors for use in treating cancer
|
|
CN116693685A
(zh)
|
2016-04-12 |
2023-09-05 |
法国施维雅药厂 |
抗tim-3抗体及组合物
|
|
WO2017190145A1
(en)
|
2016-04-29 |
2017-11-02 |
Icahn School Of Medicine At Mount Sinai |
Targeting the innate immune system to induce long-term tolerance and to resolve macrophage accumulation in atherosclerosis
|
|
IL321475A
(en)
*
|
2016-05-06 |
2025-08-01 |
Medimmune Llc |
Bispecific binding proteins and their uses
|
|
TWI822521B
(zh)
|
2016-05-13 |
2023-11-11 |
美商再生元醫藥公司 |
藉由投予pd-1抑制劑治療皮膚癌之方法
|
|
EP3458091B1
(en)
*
|
2016-05-20 |
2021-11-17 |
Eli Lilly and Company |
Combination therapy with notch and pd-1 or pd-l1 inhibitors
|
|
WO2017202962A1
(en)
|
2016-05-24 |
2017-11-30 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of non small cell lung cancer (nsclc) that coexists with chronic obstructive pulmonary disease (copd)
|
|
RU2741786C2
(ru)
|
2016-05-25 |
2021-01-28 |
Энсэрм (Энститю Насьональ Де Ла Санте Э Де Ла Решерш Медикаль) |
Способы и композиции для лечения опухолей
|
|
KR102543118B1
(ko)
|
2016-05-27 |
2023-06-14 |
아게누스 인코포레이티드 |
항-tim-3 항체 및 이의 사용 방법
|
|
MX2018014950A
(es)
*
|
2016-06-07 |
2019-04-25 |
Macrogenics Inc |
Terapia de combinacion.
|
|
CN109715196A
(zh)
|
2016-06-13 |
2019-05-03 |
转矩医疗股份有限公司 |
用于促进免疫细胞功能的组合物和方法
|
|
CA3026151A1
(en)
|
2016-06-14 |
2017-12-21 |
Xencor, Inc. |
Bispecific checkpoint inhibitor antibodies
|
|
SG11201811414TA
(en)
|
2016-06-20 |
2019-01-30 |
Incyte Corp |
Heterocyclic compounds as immunomodulators
|
|
EP3474856B1
(en)
|
2016-06-24 |
2022-09-14 |
Infinity Pharmaceuticals, Inc. |
Combination therapies
|
|
RU2019102008A
(ru)
|
2016-06-28 |
2020-07-28 |
Ксенкор, Инк. |
Гетеродимерные антитела, которые связывают рецептор соматостатина 2-го типа
|
|
EP3478321A4
(en)
|
2016-06-30 |
2020-04-22 |
Oncorus, Inc. |
PSEUDOTYPIZED ONCOLYTIC VIRAL ADMINISTRATION OF THERAPEUTIC POLYPEPTIDES
|
|
WO2018011166A2
(en)
|
2016-07-12 |
2018-01-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for quantifying the population of myeloid dendritic cells in a tissue sample
|
|
US20190248893A1
(en)
|
2016-07-14 |
2019-08-15 |
Bristol-Myers Squibb Company |
Antibodies against tim3 and uses thereof
|
|
US11365252B2
(en)
|
2016-07-20 |
2022-06-21 |
University Of Utah Research Foundation |
CD229 CAR T cells and methods of use thereof
|
|
US20180044422A1
(en)
*
|
2016-07-29 |
2018-02-15 |
New York University |
Treating solid tumor by targeting dectin-1 signaling
|
|
WO2018029336A1
(en)
|
2016-08-12 |
2018-02-15 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for determining whether a subject was administered with an activator of the ppar beta/delta pathway.
|
|
CN110087680B
(zh)
|
2016-08-19 |
2024-03-19 |
百济神州有限公司 |
使用包含btk抑制剂的组合产品治疗癌症
|
|
US10793632B2
(en)
|
2016-08-30 |
2020-10-06 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
|
WO2018046738A1
(en)
|
2016-09-12 |
2018-03-15 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting the survival time of patients suffering from cancer
|
|
WO2018046736A1
(en)
|
2016-09-12 |
2018-03-15 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting the survival time of patients suffering from cancer
|
|
EP3515453A1
(en)
|
2016-09-22 |
2019-07-31 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for reprograming immune environment in a subject in need thereof
|
|
EP3515494B1
(en)
*
|
2016-09-26 |
2026-02-25 |
The Brigham and Women's Hospital, Inc. |
Regulators of b cell-mediated immunosuppression
|
|
JP7467117B2
(ja)
|
2016-10-07 |
2024-04-15 |
ノバルティス アーゲー |
癌の治療のためのキメラ抗原受容体
|
|
MX2019004327A
(es)
|
2016-10-14 |
2019-10-14 |
Xencor Inc |
Proteinas de fusion heterodimericas biespecificas que contienen proteinas de fusion fc il-15/il-15ra y fragmentos de anticuerpo pd-1.
|
|
WO2018075447A1
(en)
|
2016-10-19 |
2018-04-26 |
The Trustees Of Columbia University In The City Of New York |
Combination of braf inhibitor, talimogene laherparepvec, and immune checkpoint inhibitor for use in the treatment cancer (melanoma)
|
|
MA50677A
(fr)
|
2016-11-01 |
2021-07-14 |
Anaptysbio Inc |
Anticorps dirigés contre la protéine d'immunoglobuline de lymphocytes t et mucine 3 (tim-3)
|
|
CN110049777A
(zh)
|
2016-11-01 |
2019-07-23 |
安奈普泰斯生物有限公司 |
针对程序性死亡-1(pd-1)的抗体
|
|
EP3538140A1
(en)
|
2016-11-14 |
2019-09-18 |
Institut National de la Sante et de la Recherche Medicale (INSERM) |
Methods and pharmaceutical compositions for modulating stem cells proliferation or differentiation
|
|
TWI780083B
(zh)
|
2016-11-18 |
2022-10-11 |
丹麥商賽門弗鎮公司 |
抗pd-1抗體及組成物
|
|
WO2018094275A1
(en)
|
2016-11-18 |
2018-05-24 |
Tolero Pharmaceuticals, Inc. |
Alvocidib prodrugs and their use as protein kinase inhibitors
|
|
US11135307B2
(en)
|
2016-11-23 |
2021-10-05 |
Mersana Therapeutics, Inc. |
Peptide-containing linkers for antibody-drug conjugates
|
|
JP2019536460A
(ja)
|
2016-12-03 |
2019-12-19 |
ジュノー セラピューティクス インコーポレイテッド |
Ｃａｒ−ｔ細胞の調節方法
|
|
WO2018106738A1
(en)
|
2016-12-05 |
2018-06-14 |
Massachusetts Institute Of Technology |
Brush-arm star polymers, conjugates and particles, and uses thereof
|
|
CN110300599B
(zh)
|
2016-12-07 |
2024-07-02 |
艾吉纳斯公司 |
抗体和其使用方法
|
|
JOP20190133A1
(ar)
*
|
2016-12-08 |
2019-06-02 |
Innovent Biologics Suzhou Co Ltd |
أجسام مضادة لـ Tim-3 لمزجها بأجسام مضادة لـ PD-1
|
|
CN110023338A
(zh)
*
|
2016-12-08 |
2019-07-16 |
伊莱利利公司 |
用于与抗pd-l1抗体组合的抗tim-3抗体
|
|
US12053512B2
(en)
|
2016-12-08 |
2024-08-06 |
Nantbio, Inc. |
Method of validating the triggering of an immune response to a neoepitope of a tumor with t-cells
|
|
WO2018119286A1
(en)
|
2016-12-22 |
2018-06-28 |
Incyte Corporation |
Bicyclic heteroaromatic compounds as immunomodulators
|
|
US10308644B2
(en)
|
2016-12-22 |
2019-06-04 |
Incyte Corporation |
Heterocyclic compounds as immunomodulators
|
|
JP2020501589A
(ja)
|
2016-12-23 |
2020-01-23 |
ウイルツ・バイオロジクス・リミテッド |
がんの治療
|
|
WO2018122249A1
(en)
|
2016-12-28 |
2018-07-05 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting the survival time of patients suffering from a microsatellite stable colorectal cancer
|
|
WO2018122245A1
(en)
|
2016-12-28 |
2018-07-05 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of predicting the survival time of patients suffering from cms3 colorectal cancer
|
|
PT3565844T
(pt)
|
2017-01-09 |
2023-05-02 |
Tesaro Inc |
Métodos de tratamento de cancro com anticorpos anti-pd-1
|
|
AU2018205401B2
(en)
|
2017-01-09 |
2025-01-02 |
Tesaro, Inc. |
Methods of treating cancer with anti-TIM-3 antibodies
|
|
WO2018132427A1
(en)
|
2017-01-10 |
2018-07-19 |
The General Hospital Corporation |
Targeted t cells with cytotoxicity toward immunosuppressive cells
|
|
US11566077B2
(en)
|
2017-01-17 |
2023-01-31 |
The University Of Chicago |
Dysfunctional antigen-specific CD8+ T cells in the tumor microenvironment
|
|
JP7062010B2
(ja)
|
2017-01-27 |
2022-05-02 |
セルジーン コーポレイション |
３－（１－オキソ－４－（（４－（（３－オキソモルホリノ）メチル）ベンジル）オキシ）イソインドリン－２－イル）ピペリジン－２，６－ジオン及びそのアイソトポログ
|
|
WO2018146148A1
(en)
|
2017-02-07 |
2018-08-16 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
A method for predicting the response to checkpoint blockade cancer immunotherapy
|
|
WO2018146128A1
(en)
|
2017-02-07 |
2018-08-16 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Detection of kit polymorphism for predicting the response to checkpoint blockade cancer immunotherapy
|
|
CN117442719A
(zh)
|
2017-02-21 |
2024-01-26 |
瑞泽恩制药公司 |
用于治疗肺癌的抗pd-1抗体
|
|
EP3585813A1
(en)
*
|
2017-02-22 |
2020-01-01 |
Sutro Biopharma, Inc. |
Pd-1/tim-3 bi-specific antibodies, compositions thereof, and methods of making and using the same
|
|
CN109983032B
(zh)
|
2017-02-27 |
2022-07-26 |
江苏恒瑞医药股份有限公司 |
Tim-3抗体、其抗原结合片段及医药用途
|
|
TW201834697A
(zh)
|
2017-02-28 |
2018-10-01 |
美商梅爾莎納醫療公司 |
Her2標靶抗體－藥物結合物之組合療法
|
|
WO2018167778A1
(en)
|
2017-03-12 |
2018-09-20 |
Yeda Research And Development Co. Ltd. |
Methods of diagnosing and prognosing cancer
|
|
WO2018167780A1
(en)
|
2017-03-12 |
2018-09-20 |
Yeda Research And Development Co. Ltd. |
Methods of prognosing and treating cancer
|
|
WO2018170133A1
(en)
|
2017-03-15 |
2018-09-20 |
Amgen Inc. |
Use of oncolytic viruses, alone or in combination with a checkpoint inhibitor, for the treatment of cancer
|
|
JP7148539B2
(ja)
*
|
2017-04-03 |
2022-10-05 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
免疫抱合体
|
|
KR102461885B1
(ko)
|
2017-04-03 |
2022-11-03 |
에프. 호프만-라 로슈 아게 |
항-pd-1 항체와 돌연변이 il-2 또는 il-15의 면역접합체
|
|
AU2018247916B2
(en)
*
|
2017-04-05 |
2025-04-24 |
Les Laboratoires Servier |
Combination therapies targeting PD-1, TIM-3, and LAG-3
|
|
CA3052532A1
(en)
|
2017-04-05 |
2018-10-11 |
F. Hoffmann-La Roche Ag |
Bispecific antibodies specifically binding to pd1 and lag3
|
|
AR111651A1
(es)
|
2017-04-28 |
2019-08-07 |
Novartis Ag |
Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
|
|
EP3615068A1
(en)
|
2017-04-28 |
2020-03-04 |
Novartis AG |
Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
|
|
MX2019012741A
(es)
|
2017-04-28 |
2020-01-21 |
Merck Sharp & Dohme |
Biomarcadores para agentes terapeuticos contra el cancer.
|
|
EP3615055A1
(en)
|
2017-04-28 |
2020-03-04 |
Novartis AG |
Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
|
|
AR111960A1
(es)
|
2017-05-26 |
2019-09-04 |
Incyte Corp |
Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
|
|
IL327498A
(en)
|
2017-06-02 |
2026-05-01 |
Juno Therapeutics Inc |
Articles of manufacture and methods for treatment using adoptive cell therapy
|
|
WO2018229715A1
(en)
|
2017-06-16 |
2018-12-20 |
Novartis Ag |
Compositions comprising anti-cd32b antibodies and methods of use thereof
|
|
EP3641739A1
(en)
|
2017-06-20 |
2020-04-29 |
Institut Curie |
Inhibitor of suv39h1 histone methyltransferase for use in cancer combination therapy
|
|
US20200172628A1
(en)
|
2017-06-22 |
2020-06-04 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
|
IL271491B2
(en)
|
2017-06-22 |
2023-09-01 |
Celgene Corp |
Treatment of carcinoma of the liver characterized by hepatitis b virus infection
|
|
WO2018234879A1
(en)
|
2017-06-22 |
2018-12-27 |
Novartis Ag |
USE OF IL-1β BINDING ANTIBODIES IN THE TREATMENT OF CANCER
|
|
MX2019015885A
(es)
|
2017-06-22 |
2020-09-10 |
Novartis Ag |
Moleculas de anticuerpo que se unen a cd73 y usos de las mismas.
|
|
CN111050791A
(zh)
|
2017-06-27 |
2020-04-21 |
诺华股份有限公司 |
用于抗tim-3抗体的给药方案及其用途
|
|
CN111050545A
(zh)
|
2017-06-29 |
2020-04-21 |
朱诺治疗学股份有限公司 |
评估与免疫疗法相关的毒性的小鼠模型
|
|
EP4201399A3
(en)
|
2017-06-30 |
2023-08-09 |
Celgene Corporation |
Compositions and methods of use of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl) methyl) -2,2-difluoroacetamide
|
|
TWI887193B
(zh)
*
|
2017-07-06 |
2025-06-21 |
荷蘭商米樂斯股份有限公司 |
藉由細胞表現之調控生物活性的抗體
|
|
JP7258009B2
(ja)
|
2017-07-10 |
2023-04-14 |
セルジーン コーポレイション |
抗増殖化合物及びその使用方法
|
|
WO2019018730A1
(en)
|
2017-07-20 |
2019-01-24 |
Novartis Ag |
DOSAGE REGIMES FOR ANTI-LAG3 ANTIBODIES AND USES THEREOF
|
|
US11926664B2
(en)
|
2017-07-25 |
2024-03-12 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for modulating monocytopoiesis
|
|
JP2021500916A
(ja)
|
2017-07-28 |
2021-01-14 |
フェインズ セラピューティクス，インコーポレーテッド |
抗ｔｉｍ−３抗体及びその使用
|
|
KR20250020679A
(ko)
|
2017-08-04 |
2025-02-11 |
젠맵 에이/에스 |
Pd-l1 및 cd137에 결합하는 결합제 및 그의 용도
|
|
AU2018323462A1
(en)
|
2017-08-28 |
2020-03-26 |
Bristol-Myers Squibb Company |
TIM-3 antagonists for the treatment and diagnosis of cancers
|
|
JP7196160B2
(ja)
|
2017-09-12 |
2022-12-26 |
スミトモ ファーマ オンコロジー， インコーポレイテッド |
Ｍｃｌ－１阻害剤アルボシジブを用いた、ｂｃｌ－２阻害剤に対して非感受性である癌の治療レジメン
|
|
WO2019057744A1
(en)
|
2017-09-19 |
2019-03-28 |
Institut Curie |
AROMATIC HYDROCARBON RECEPTOR AGONIST FOR USE IN ASSOCIATION TREATMENT AGAINST CANCER
|
|
WO2019081983A1
(en)
|
2017-10-25 |
2019-05-02 |
Novartis Ag |
CD32B TARGETING ANTIBODIES AND METHODS OF USE
|
|
WO2019084553A1
(en)
|
2017-10-27 |
2019-05-02 |
New York University |
ANTI-GALECTIN-9 ANTIBODIES AND USES THEREOF
|
|
WO2019089858A2
(en)
|
2017-11-01 |
2019-05-09 |
Juno Therapeutics, Inc. |
Methods of assessing or monitoring a response to a cell therapy
|
|
MA49911A
(fr)
|
2017-11-01 |
2020-06-24 |
Juno Therapeutics Inc |
Anticorps et récepteurs antigéniques chimériques spécifiques de l'antigene de maturation des lymphocytes b
|
|
US11066475B2
(en)
|
2017-11-01 |
2021-07-20 |
Juno Therapeutics, Inc. |
Chimeric antigen receptors specific for B-cell maturation antigen and encoding polynucleotides
|
|
AU2018359907A1
(en)
|
2017-11-06 |
2020-05-07 |
Fred Hutchinson Cancer Center |
Combination of a cell therapy and a gamma secretase inhibitor
|
|
AU2018366199A1
(en)
|
2017-11-08 |
2020-05-28 |
Xencor, Inc. |
Bispecific and monospecific antibodies using novel anti-PD-1 sequences
|
|
US10981992B2
(en)
|
2017-11-08 |
2021-04-20 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
|
CN111315398A
(zh)
|
2017-11-10 |
2020-06-19 |
阿尔莫生物科技股份有限公司 |
白介素-10与免疫检查点途径抑制剂的组合的组合物和使用方法
|
|
MX2020004756A
(es)
|
2017-11-16 |
2020-08-20 |
Novartis Ag |
Terapias de combinacion.
|
|
IL314506A
(en)
|
2017-11-24 |
2024-09-01 |
Inst Nat Sante Rech Med |
Methods and preparations for the treatment of cancer
|
|
US11638760B2
(en)
|
2017-11-27 |
2023-05-02 |
Mersana Therapeutics, Inc. |
Pyrrolobenzodiazepine antibody conjugates
|
|
MX2020005651A
(es)
|
2017-11-30 |
2020-10-28 |
Novartis Ag |
Receptor de antigeno quimerico dirigido a bcma y usos del mismo.
|
|
EP3724225A1
(en)
|
2017-12-15 |
2020-10-21 |
Juno Therapeutics, Inc. |
Anti-cct5 binding molecules and methods of use thereof
|
|
JP7765181B2
(ja)
|
2017-12-19 |
2025-11-06 |
ゼンコア インコーポレイテッド |
改変されたｉｌ－２ ｆｃ融合タンパク質
|
|
CN111757757A
(zh)
|
2017-12-21 |
2020-10-09 |
梅尔莎纳医疗公司 |
吡咯并苯并二氮呯抗体共轭物
|
|
KR20200105678A
(ko)
|
2017-12-28 |
2020-09-08 |
더 제너럴 하스피탈 코포레이션 |
Cbm 시그날로좀 복합체 표적화는 조절 t 세포의 종양 미세환경에 대한 염증유발을 유도함
|
|
WO2019133847A1
(en)
|
2017-12-29 |
2019-07-04 |
Oncorus, Inc. |
Oncolytic viral delivery of therapeutic polypeptides
|
|
WO2019136432A1
(en)
|
2018-01-08 |
2019-07-11 |
Novartis Ag |
Immune-enhancing rnas for combination with chimeric antigen receptor therapy
|
|
KR20200109339A
(ko)
|
2018-01-16 |
2020-09-22 |
브리스톨-마이어스 스큅 컴퍼니 |
Tim3에 대한 항체를 사용하여 암을 치료하는 방법
|
|
US12398209B2
(en)
|
2018-01-22 |
2025-08-26 |
Janssen Biotech, Inc. |
Methods of treating cancers with antagonistic anti-PD-1 antibodies
|
|
CN111971059A
(zh)
|
2018-01-31 |
2020-11-20 |
细胞基因公司 |
使用过继细胞疗法和检查点抑制剂的组合疗法
|
|
AU2019215031C1
(en)
|
2018-01-31 |
2026-02-26 |
Novartis Ag |
Combination therapy using a chimeric antigen receptor
|
|
WO2019160956A1
(en)
|
2018-02-13 |
2019-08-22 |
Novartis Ag |
Chimeric antigen receptor therapy in combination with il-15r and il15
|
|
AU2019227607C1
(en)
|
2018-02-27 |
2023-07-20 |
Incyte Corporation |
Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitors
|
|
WO2019170727A1
(en)
|
2018-03-06 |
2019-09-12 |
Institut Curie |
Inhibitor of setdb1 histone methyltransferase for use in cancer combination therapy
|
|
JP7351845B2
(ja)
|
2018-03-23 |
2023-09-27 |
ブリストル－マイヤーズ スクイブ カンパニー |
Ｍｉｃａおよび／またはｍｉｃｂに対する抗体ならびにそれらの使用
|
|
WO2019185792A1
(en)
|
2018-03-29 |
2019-10-03 |
Philogen S.P.A |
Cancer treatment using immunoconjugates and immune check-point inhibitors
|
|
SMT202300065T1
(it)
|
2018-03-30 |
2023-05-12 |
Incyte Corp |
Composti eterociclici come immunomodulatori
|
|
CN112469477A
(zh)
|
2018-04-04 |
2021-03-09 |
Xencor股份有限公司 |
与成纤维细胞活化蛋白结合的异源二聚体抗体
|
|
US20210147547A1
(en)
|
2018-04-13 |
2021-05-20 |
Novartis Ag |
Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
|
|
KR20210003814A
(ko)
|
2018-04-18 |
2021-01-12 |
젠코어 인코포레이티드 |
IL-15/IL-15Rα Fc-융합 단백질 및 TIM-3 항원 결합 도메인을 함유하는 TIM-3 표적화 이종이량체 융합 단백질
|
|
CA3097593A1
(en)
|
2018-04-18 |
2019-10-24 |
Xencor, Inc. |
Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
|
|
WO2019207030A1
(en)
|
2018-04-26 |
2019-10-31 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting a response with an immune checkpoint inhibitor in a patient suffering from a lung cancer
|
|
US20210047405A1
(en)
|
2018-04-27 |
2021-02-18 |
Novartis Ag |
Car t cell therapies with enhanced efficacy
|
|
US20210396739A1
(en)
|
2018-05-01 |
2021-12-23 |
Novartis Ag |
Biomarkers for evaluating car-t cells to predict clinical outcome
|
|
RS66310B1
(sr)
|
2018-05-04 |
2025-01-31 |
Incyte Corp |
Čvrsti oblici inhibitora fgfr i procesi za njegovu pripremu
|
|
KR102956194B1
(ko)
|
2018-05-04 |
2026-04-23 |
인사이트 코포레이션 |
Fgfr 억제제의 염
|
|
CN112752756B
(zh)
|
2018-05-11 |
2024-06-25 |
因赛特公司 |
作为PD-L1免疫调节剂的四氢-咪唑并[4,5-c]吡啶衍生物
|
|
EP3810610A1
(en)
|
2018-05-18 |
2021-04-28 |
Incyte Corporation |
Fused pyrimidine derivatives as a2a / a2b inhibitors
|
|
IL278854B2
(en)
|
2018-05-23 |
2026-01-01 |
Celgene Corp |
Multiple myeloma treatment and biomarker use for 4-(4-(4-(((2-(6,2-dioxopyridin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl-3-fluorobenzonitrile
|
|
PL3796912T3
(pl)
|
2018-05-23 |
2023-09-11 |
Celgene Corporation |
Związki przeciwproliferacyjne i przeciwciało bispecyficzne przeciwko bcma i cd3 do zastosowania kombinowanego
|
|
UY38247A
(es)
|
2018-05-30 |
2019-12-31 |
Novartis Ag |
Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
|
|
WO2019232244A2
(en)
|
2018-05-31 |
2019-12-05 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
|
PE20210320A1
(es)
|
2018-06-01 |
2021-02-16 |
Novartis Ag |
Moleculas de union contra bcma y usos de las mismas
|
|
IL279367B2
(en)
|
2018-06-13 |
2026-05-01 |
Novartis Ag |
BCMA chimeric antigen receptors and their uses
|
|
JP7097465B2
(ja)
|
2018-06-19 |
2022-07-07 |
アルモ・バイオサイエンシーズ・インコーポレイテッド |
キメラ抗原受容体細胞療法と併用するｉｌ－１０剤の組成およびその使用方法
|
|
EP3819313A4
(en)
*
|
2018-07-03 |
2021-09-01 |
L&L Biopharma Co., Ltd. |
BISPECIFIC ANTIBODY AND USE OF IT
|
|
CN117304191A
(zh)
|
2018-07-05 |
2023-12-29 |
因赛特公司 |
作为a2a/a2b抑制剂的稠合吡嗪衍生物
|
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
|
BR122022012697B1
(pt)
|
2018-07-10 |
2023-04-04 |
Novartis Ag |
Usos de derivados de 3-(5-hidróxi-1-oxoisoindolin-2-il)piperidina-2,6- diona, e kit
|
|
JP2021531306A
(ja)
|
2018-07-25 |
2021-11-18 |
アドバンスド アクセラレーター アプリケーションズ エスエー |
神経内分泌腫瘍の処置の方法
|
|
US12599662B2
(en)
|
2018-08-06 |
2026-04-14 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating cancers
|
|
AU2019323435A1
(en)
|
2018-08-20 |
2021-02-18 |
Jiangsu Hengrui Medicine Co., Ltd. |
Use of TIM-3 antibody in preparation of medicines for treating tumors
|
|
JP2022513553A
(ja)
|
2018-08-28 |
2022-02-09 |
ジエンス ヘンルイ メデイシンカンパニー リミテッド |
抗ｔｉｍ３抗体医薬組成物およびその使用
|
|
US20210347851A1
(en)
|
2018-09-28 |
2021-11-11 |
Novartis Ag |
Cd19 chimeric antigen receptor (car) and cd22 car combination therapies
|
|
WO2020069405A1
(en)
|
2018-09-28 |
2020-04-02 |
Novartis Ag |
Cd22 chimeric antigen receptor (car) therapies
|
|
WO2020070062A1
(en)
|
2018-10-01 |
2020-04-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of tim-3 inhibitors for the treatment of exacerbations in patients suffering from severe asthma
|
|
KR102884523B1
(ko)
|
2018-10-03 |
2025-11-10 |
젠코어 인코포레이티드 |
IL-12 이종이량체 Fc-융합 단백질
|
|
US11066404B2
(en)
|
2018-10-11 |
2021-07-20 |
Incyte Corporation |
Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
|
|
WO2020079692A1
(en)
|
2018-10-17 |
2020-04-23 |
Biolinerx Ltd. |
Treatment of metastatic pancreatic adenocarcinoma
|
|
CN112955462B
(zh)
|
2018-10-18 |
2024-05-07 |
国家医疗保健研究所 |
用于治疗实体瘤的βIG-H3拮抗剂和免疫检查点抑制剂的组合
|
|
CA3117050A1
(en)
|
2018-10-29 |
2020-05-07 |
Mersana Therapeutics, Inc. |
Cysteine engineered antibody-drug conjugates with peptide-containing linkers
|
|
CN119569895A
(zh)
|
2018-11-01 |
2025-03-07 |
朱诺治疗学股份有限公司 |
G蛋白偶合受体c类5族成员d(gprc5d)特异性嵌合抗原受体
|
|
US12473345B2
(en)
|
2018-11-01 |
2025-11-18 |
Juno Therapeutics, Inc. |
Methods for treatment using chimeric antigen receptors specific for B-cell maturation antigen
|
|
DK3880186T3
(da)
|
2018-11-14 |
2024-06-03 |
Regeneron Pharma |
Intralæsional administration af pd-1-hæmmere til behandling af hudcancer
|
|
BR112021009420A2
(pt)
|
2018-11-16 |
2021-11-23 |
Juno Therapeutics Inc |
Métodos de dosagem de células t manipuladas para o tratamento de malignidades de células b
|
|
CA3120576A1
(en)
|
2018-11-26 |
2020-06-04 |
Massachusetts Institute Of Technology |
Compositions and methods for immune tolerance
|
|
EP4427810A3
(en)
|
2018-11-30 |
2024-12-04 |
Juno Therapeutics, Inc. |
Methods for treatment using adoptive cell therapy
|
|
EA202191201A1
(ru)
|
2018-12-03 |
2022-01-26 |
Эдженсис, Инк. |
Фармацевтические композиции, включающие конъюгаты анти-191p4d12 антитело-лекарственное средство, и способы их применения
|
|
US11034710B2
(en)
|
2018-12-04 |
2021-06-15 |
Sumitomo Dainippon Pharma Oncology, Inc. |
CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
|
|
AU2019402189B2
(en)
|
2018-12-20 |
2023-04-13 |
Novartis Ag |
Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
|
|
US20210386763A1
(en)
|
2018-12-20 |
2021-12-16 |
Novartis Ag |
Pharmaceutical combinations
|
|
US20220025036A1
(en)
|
2018-12-21 |
2022-01-27 |
Novartis Ag |
Use of il-1beta binding antibodies
|
|
BR112021012066A2
(pt)
|
2018-12-21 |
2021-11-03 |
Onxeo |
Novas moléculas de ácido nucleico conjugadas e seus usos
|
|
WO2020128637A1
(en)
|
2018-12-21 |
2020-06-25 |
Novartis Ag |
Use of il-1 binding antibodies in the treatment of a msi-h cancer
|
|
JP2022516850A
(ja)
|
2018-12-21 |
2022-03-03 |
ノバルティス アーゲー |
骨髄異形成症候群の治療又は予防におけるＩＬ－１β抗体の使用
|
|
US20220056123A1
(en)
|
2018-12-21 |
2022-02-24 |
Novartis Ag |
Use of il-1beta binding antibodies
|
|
MX2021007639A
(es)
|
2018-12-27 |
2021-08-11 |
Amgen Inc |
Formulaciones de virus liofilizadas.
|
|
MX2021008121A
(es)
|
2019-01-03 |
2021-12-10 |
Inst Nat Sante Rech Med |
Metodos y composiciones farmaceuticas para mejorar las respuestas inmunitarias dependientes de celulas t cd8+ en sujetos que sufren de cancer.
|
|
DK3908281T3
(da)
|
2019-01-09 |
2024-10-21 |
Celgene Corp |
Antiproliferative forbindelser og sekundære aktive midler til anvendelse til behandling af multipelt myelom
|
|
AU2020206692B2
(en)
|
2019-01-09 |
2025-03-27 |
Celgene Corporation |
Pharmaceutical compositions comprising (S)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl) benzyl)piperazin-1-yl)-3-fluorobenzonitrile and methods of using the same
|
|
EP3908582B1
(en)
|
2019-01-09 |
2025-11-12 |
Celgene Corporation |
Solid forms comprising (s)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl) benzyl)piperazin-1-yl)-3-fluorobenzonitrile and salts thereof, and compositions comprising and methods of using the same
|
|
EA202192103A1
(ru)
|
2019-01-29 |
2021-12-15 |
Джуно Терапьютикс, Инк. |
Антитела и химерные антигенные рецепторы, специфичные к орфанному рецептору типа рецеторной тирозинкиназы 1 (ror1)
|
|
TWI829857B
(zh)
|
2019-01-29 |
2024-01-21 |
美商英塞特公司 |
作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
|
|
HUE072069T2
(hu)
|
2019-02-12 |
2025-10-28 |
Sumitomo Pharma America Inc |
2-((1R,4R)-4-((3-(3-(trifluormetil)fenil)imidazo[1,2- b]piridazin-6-il)amino)ciklohexil)propán-2-ol sósavas sójának kristályos formája
|
|
WO2020168197A1
(en)
|
2019-02-15 |
2020-08-20 |
Incyte Corporation |
Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors
|
|
CA3123519A1
(en)
|
2019-02-15 |
2020-08-20 |
Novartis Ag |
Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
EP3924054B1
(en)
|
2019-02-15 |
2025-04-02 |
Novartis AG |
3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
EA202192260A1
(ru)
|
2019-02-15 |
2021-12-17 |
Инсайт Корпорейшн |
Биомаркеры циклин-зависимой киназы 2 и их применение
|
|
EP3930850A1
(en)
|
2019-03-01 |
2022-01-05 |
Xencor, Inc. |
Heterodimeric antibodies that bind enpp3 and cd3
|
|
WO2020180864A1
(en)
|
2019-03-05 |
2020-09-10 |
Amgen Inc. |
Use of oncolytic viruses for the treatment of cancer
|
|
TW202100520A
(zh)
|
2019-03-05 |
2021-01-01 |
美商英塞特公司 |
作為cdk2 抑制劑之吡唑基嘧啶基胺化合物
|
|
WO2020185532A1
(en)
|
2019-03-08 |
2020-09-17 |
Incyte Corporation |
Methods of treating cancer with an fgfr inhibitor
|
|
JP2022525149A
(ja)
|
2019-03-20 |
2022-05-11 |
スミトモ ダイニッポン ファーマ オンコロジー， インコーポレイテッド |
ベネトクラクスが失敗した急性骨髄性白血病（ａｍｌ）の処置
|
|
AU2020245437A1
(en)
|
2019-03-22 |
2021-09-30 |
Sumitomo Pharma Oncology, Inc. |
Compositions comprising PKM2 modulators and methods of treatment using the same
|
|
US11919904B2
(en)
|
2019-03-29 |
2024-03-05 |
Incyte Corporation |
Sulfonylamide compounds as CDK2 inhibitors
|
|
TW202102543A
(zh)
|
2019-03-29 |
2021-01-16 |
美商安進公司 |
溶瘤病毒在癌症新輔助療法中之用途
|
|
US20220289854A1
(en)
|
2019-04-30 |
2022-09-15 |
Dana-Farber Cancer Institute, Inc. |
Methods for treating cancer using combinations of anti-cx3cr1 and immune checkpoint blockade agents
|
|
WO2020223469A1
(en)
|
2019-05-01 |
2020-11-05 |
Incyte Corporation |
N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer
|
|
WO2020223558A1
(en)
|
2019-05-01 |
2020-11-05 |
Incyte Corporation |
Tricyclic amine compounds as cdk2 inhibitors
|
|
IL287801A
(en)
|
2019-05-07 |
2022-07-01 |
Immunicom Inc |
Increasing responses to checkpoint inhibitors by extracorporeal apheresis
|
|
WO2020243570A1
(en)
|
2019-05-30 |
2020-12-03 |
Bristol-Myers Squibb Company |
Cell localization signature and combination therapy
|
|
JP2022534982A
(ja)
|
2019-05-30 |
2022-08-04 |
ブリストル－マイヤーズ スクイブ カンパニー |
細胞局在化シグネチャーおよびその使用
|
|
US20220363760A1
(en)
|
2019-05-30 |
2022-11-17 |
Bristol-Myers Squibb Company |
Multi-tumor gene signature for suitability to immuno-oncology therapy
|
|
BR112021026832A2
(pt)
|
2019-07-02 |
2022-05-10 |
Hutchinson Fred Cancer Res |
Vetores ad35 recombinantes e aprimoramentos da terapia gênica relacionada
|
|
AU2020300619A1
(en)
|
2019-07-03 |
2022-01-27 |
Sumitomo Pharma Oncology, Inc. |
Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof
|
|
WO2021007269A1
(en)
|
2019-07-09 |
2021-01-14 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
WO2021024020A1
(en)
|
2019-08-06 |
2021-02-11 |
Astellas Pharma Inc. |
Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
|
|
WO2021030537A1
(en)
|
2019-08-14 |
2021-02-18 |
Incyte Corporation |
Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors
|
|
JP2022548627A
(ja)
|
2019-09-16 |
2022-11-21 |
ノバルティス アーゲー |
骨髄線維症の治療のための、高親和性のリガンドを遮断するヒト化抗ｔ細胞免疫グロブリンドメイン及びムチンドメイン３（ｔｉｍ－３）ｉｇｇ４抗体の使用
|
|
JP2022548881A
(ja)
|
2019-09-18 |
2022-11-22 |
ノバルティス アーゲー |
Ｅｎｔｐｄ２抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法
|
|
JP7559059B2
(ja)
|
2019-09-30 |
2024-10-01 |
インサイト・コーポレイション |
免疫調節剤としてのピリド［３，２－ｄ］ピリミジン化合物
|
|
US12122767B2
(en)
|
2019-10-01 |
2024-10-22 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
CR20220170A
(es)
|
2019-10-11 |
2022-10-10 |
Incyte Corp |
Aminas bicíclicas como inhibidoras de la cdk2
|
|
GEP20247679B
(en)
|
2019-10-14 |
2024-10-10 |
Incyte Corp |
Bicyclic heterocycles as fgfr inhibitors
|
|
US11566028B2
(en)
|
2019-10-16 |
2023-01-31 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
WO2021079195A1
(en)
|
2019-10-21 |
2021-04-29 |
Novartis Ag |
Tim-3 inhibitors and uses thereof
|
|
CN114786679A
(zh)
|
2019-10-21 |
2022-07-22 |
诺华股份有限公司 |
具有维奈托克和tim-3抑制剂的组合疗法
|
|
CA3157196A1
(en)
|
2019-11-05 |
2021-05-14 |
Celgene Corporation |
Combination therapy with 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl) methyl)-2,2-difluoroacetamide
|
|
EP4058461A1
(en)
|
2019-11-11 |
2022-09-21 |
Incyte Corporation |
Salts and crystalline forms of a pd-1/pd-l1 inhibitor
|
|
JP7805928B2
(ja)
|
2019-11-26 |
2026-01-26 |
ノバルティス アーゲー |
Ｃｄ１９及びｃｄ２２キメラ抗原受容体及びその使用
|
|
MX2022006691A
(es)
|
2019-12-04 |
2022-09-19 |
Incyte Corp |
Derivados de un inhibidor de receptores del factor de crecimiento de fibroblastos (fgfr).
|
|
WO2021113479A1
(en)
|
2019-12-04 |
2021-06-10 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
US20230057071A1
(en)
|
2019-12-20 |
2023-02-23 |
Novartis Ag |
Combination of anti tim-3 antibody mbg453 and anti tgf-beta antibody nis793, with or without decitabine or the anti pd-1 antibody spartalizumab, for treating myelofibrosis and myelodysplastic syndrome
|
|
CN115279766B
(zh)
|
2020-01-03 |
2025-05-02 |
因赛特公司 |
包含a2a/a2b和pd-1/pd-l1抑制剂的组合疗法
|
|
CN115362168A
(zh)
|
2020-01-14 |
2022-11-18 |
辛德凯因股份有限公司 |
偏向化il2突变蛋白方法和组合物
|
|
US12012409B2
(en)
|
2020-01-15 |
2024-06-18 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
EP4090335A1
(en)
|
2020-01-17 |
2022-11-23 |
Novartis AG |
Combination comprising a tim-3 inhibitor and a hypomethylating agent for use in treating myelodysplastic syndrome or chronic myelomonocytic leukemia
|
|
PH12022552347A1
(en)
|
2020-03-06 |
2024-01-29 |
Incyte Corp |
Combination therapy comprising axl/mer and pd-1/pd-l1 inhibitors
|
|
US20230093147A1
(en)
|
2020-03-09 |
2023-03-23 |
President And Fellows Of Harvard College |
Methods and compositions relating to improved combination therapies
|
|
IL297147B1
(en)
|
2020-04-10 |
2026-05-01 |
Juno Therapeutics Inc |
Methods and uses related to engineered cell therapy with a chimeric antigen receptor directed against a B-cell maturation antigen
|
|
CN121270550A
(zh)
|
2020-04-16 |
2026-01-06 |
因赛特公司 |
稠合三环kras抑制剂
|
|
BR112022021426A2
(pt)
*
|
2020-04-22 |
2022-12-13 |
Akeso Biopharma Inc |
Anticorpo biespecífico anti-cd73/anti-pd-1, molécula de ácido nucleico isolada, vetor, célula hospedeira, método para preparar o anticorpo biespecífico anti-cd73/anti-pd-1, conjugado, kit, usos do anticorpo biespecífico anti-cd73/anti-pd-1, composição farmacêutica, método in vitro, linhagem celular de hibridoma e anticorpo monoclonal anti-cd73
|
|
WO2021231526A1
(en)
|
2020-05-13 |
2021-11-18 |
Incyte Corporation |
Fused pyrimidine compounds as kras inhibitors
|
|
EP4149632A1
(en)
|
2020-05-14 |
2023-03-22 |
Xencor, Inc. |
Heterodimeric antibodies that bind msln and cd3
|
|
WO2021231976A1
(en)
|
2020-05-14 |
2021-11-18 |
Xencor, Inc. |
Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
|
|
CA3180060A1
(en)
|
2020-05-29 |
2021-12-02 |
Zongmin ZHAO |
Living cells engineered with polyphenol-functionalized biologically active nanocomplexes
|
|
AR122644A1
(es)
|
2020-06-19 |
2022-09-28 |
Onxeo |
Nuevas moléculas de ácido nucleico conjugado y sus usos
|
|
EP4168007A1
(en)
|
2020-06-23 |
2023-04-26 |
Novartis AG |
Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
|
|
US20230293530A1
(en)
|
2020-06-24 |
2023-09-21 |
Yeda Research And Development Co. Ltd. |
Agents for sensitizing solid tumors to treatment
|
|
US20230235077A1
(en)
|
2020-06-24 |
2023-07-27 |
The General Hospital Corporation |
Materials and methods of treating cancer
|
|
CN115916191B
(zh)
|
2020-06-25 |
2026-06-23 |
新基公司 |
用组合疗法治疗癌症的方法
|
|
JP7741831B2
(ja)
|
2020-06-30 |
2025-09-18 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
術前補助療法及び根治手術後の固形がんを患っている患者の再発及び／又は死亡のリスクを予測するための方法
|
|
EP4172621A1
(en)
|
2020-06-30 |
2023-05-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting the risk of recurrence and/or death of patients suffering from a solid cancer after preoperative adjuvant therapies
|
|
ES2988714T3
(es)
|
2020-07-07 |
2024-11-21 |
Celgene Corp |
Composiciones farmacéuticas que comprenden (S)-4-(4-(4-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-4-il)oxi)metil)bencilo)piperazin-1-il)-3-fluorobenzonitrilo y métodos de uso de las mismas
|
|
CN116234568A
(zh)
|
2020-07-07 |
2023-06-06 |
生物技术公司 |
用于hpv阳性癌症的治疗性rna
|
|
EP4188549A1
(en)
|
2020-08-03 |
2023-06-07 |
Novartis AG |
Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
US11919958B2
(en)
|
2020-08-19 |
2024-03-05 |
Xencor, Inc. |
Anti-CD28 compositions
|
|
WO2022047093A1
(en)
|
2020-08-28 |
2022-03-03 |
Incyte Corporation |
Vinyl imidazole compounds as inhibitors of kras
|
|
WO2022043558A1
(en)
|
2020-08-31 |
2022-03-03 |
Advanced Accelerator Applications International Sa |
Method of treating psma-expressing cancers
|
|
IL300916A
(en)
|
2020-08-31 |
2023-04-01 |
Bristol Myers Squibb Co |
Cell localization signature and immunotherapy
|
|
US20230321285A1
(en)
|
2020-08-31 |
2023-10-12 |
Advanced Accelerator Applications International Sa |
Method of treating psma-expressing cancers
|
|
KR20230061499A
(ko)
|
2020-09-03 |
2023-05-08 |
리제너론 파마슈티칼스 인코포레이티드 |
Pd-1 저해제 투여에 의한 암 통증 치료 방법
|
|
WO2022072783A1
(en)
|
2020-10-02 |
2022-04-07 |
Incyte Corporation |
Bicyclic dione compounds as inhibitors of kras
|
|
US11780836B2
(en)
|
2020-11-06 |
2023-10-10 |
Incyte Corporation |
Process of preparing a PD-1/PD-L1 inhibitor
|
|
US11760756B2
(en)
|
2020-11-06 |
2023-09-19 |
Incyte Corporation |
Crystalline form of a PD-1/PD-L1 inhibitor
|
|
IL302590A
(en)
|
2020-11-06 |
2023-07-01 |
Incyte Corp |
Process for preparing PD-1/PD-L1 inhibitor and salts and crystalline forms thereof
|
|
AU2021373366A1
(en)
|
2020-11-06 |
2023-06-01 |
Novartis Ag |
Cd19 binding molecules and uses thereof
|
|
TW202233248A
(zh)
|
2020-11-08 |
2022-09-01 |
美商西健公司 |
組合療法
|
|
WO2022120179A1
(en)
|
2020-12-03 |
2022-06-09 |
Bristol-Myers Squibb Company |
Multi-tumor gene signatures and uses thereof
|
|
TW202237119A
(zh)
|
2020-12-10 |
2022-10-01 |
美商住友製藥腫瘤公司 |
Ａｌｋ﹘５抑制劑和彼之用途
|
|
WO2022135667A1
(en)
|
2020-12-21 |
2022-06-30 |
BioNTech SE |
Therapeutic rna for treating cancer
|
|
TW202245808A
(zh)
|
2020-12-21 |
2022-12-01 |
德商拜恩迪克公司 |
用於治療癌症之治療性ｒｎａ
|
|
WO2022135666A1
(en)
|
2020-12-21 |
2022-06-30 |
BioNTech SE |
Treatment schedule for cytokine proteins
|
|
AU2021416156A1
(en)
|
2020-12-28 |
2023-06-22 |
Bristol-Myers Squibb Company |
Methods of treating tumors
|
|
PT4267105T
(pt)
|
2020-12-28 |
2025-04-30 |
Bristol Myers Squibb Co |
Composições de anticorpos e métodos de utilização das mesmas
|
|
JP2024502005A
(ja)
|
2020-12-29 |
2024-01-17 |
インサイト・コーポレイション |
Ａ２ａ／ａ２ｂ阻害剤、ｐｄ－１／ｐｄ－ｌ１阻害剤、及び抗ｃｄ７３抗体を含む併用療法
|
|
US20250163162A1
(en)
|
2021-01-11 |
2025-05-22 |
Synthekine, Inc. |
Compositions and methods related to receptor pairing
|
|
CA3206549A1
(en)
|
2021-01-29 |
2022-08-04 |
Frederick G. Vogt |
Methods of making modified tumor infiltrating lymphocytes and their use in adoptive cell therapy
|
|
CN117222413A
(zh)
|
2021-02-10 |
2023-12-12 |
同润生物医药(上海)有限公司 |
治疗肿瘤的方法和组合
|
|
EP4305067A1
(en)
|
2021-03-09 |
2024-01-17 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and cldn6
|
|
US11859012B2
(en)
|
2021-03-10 |
2024-01-02 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and GPC3
|
|
CN118459539B
(zh)
|
2021-03-19 |
2026-01-06 |
生物治疗探索股份有限公司 |
用于调节训练免疫的化合物及其使用方法
|
|
TW202304506A
(zh)
|
2021-03-25 |
2023-02-01 |
日商安斯泰來製藥公司 |
涉及抗claudin 18.2抗體的組合治療以治療癌症
|
|
JP2024514530A
(ja)
|
2021-04-02 |
2024-04-02 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
切断型ｃｄｃｐ１に対する抗体およびその使用
|
|
US20250319183A1
(en)
|
2021-04-07 |
2025-10-16 |
David Avigan |
Compositions and methods for the treatment of cancer
|
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
|
|
JP2024514816A
(ja)
|
2021-04-09 |
2024-04-03 |
シージェン インコーポレイテッド |
抗ｔｉｇｉｔ抗体を用いるがんの治療方法
|
|
EP4323405A1
(en)
|
2021-04-12 |
2024-02-21 |
Incyte Corporation |
Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
|
|
TW202309022A
(zh)
|
2021-04-13 |
2023-03-01 |
美商努法倫特公司 |
用於治療具egfr突變之癌症之胺基取代雜環
|
|
CA3212610A1
(en)
|
2021-04-20 |
2022-10-27 |
Philip MOQUIST |
Modulation of antibody-dependent cellular cytotoxicity
|
|
AR125874A1
(es)
|
2021-05-18 |
2023-08-23 |
Novartis Ag |
Terapias de combinación
|
|
WO2022254337A1
(en)
|
2021-06-01 |
2022-12-08 |
Novartis Ag |
Cd19 and cd22 chimeric antigen receptors and uses thereof
|
|
CA3220274A1
(en)
|
2021-06-09 |
2022-12-15 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
TW202313610A
(zh)
|
2021-06-09 |
2023-04-01 |
美商英塞特公司 |
作為ｆｇｆｒ抑制劑之三環雜環
|
|
US11981671B2
(en)
|
2021-06-21 |
2024-05-14 |
Incyte Corporation |
Bicyclic pyrazolyl amines as CDK2 inhibitors
|
|
WO2023283213A1
(en)
|
2021-07-07 |
2023-01-12 |
Incyte Corporation |
Tricyclic compounds as inhibitors of kras
|
|
WO2023285552A1
(en)
|
2021-07-13 |
2023-01-19 |
BioNTech SE |
Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
|
|
CA3224841A1
(en)
|
2021-07-14 |
2023-01-19 |
Zhenwu Li |
Tricyclic compounds as inhibitors of kras
|
|
EP4370139A4
(en)
|
2021-07-14 |
2025-10-15 |
Synthekine Inc |
METHODS AND COMPOSITIONS FOR USE IN CELL THERAPY FOR NEOPLASTIC DISEASE
|
|
CA3229855A1
(en)
|
2021-08-31 |
2023-03-09 |
Incyte Corporation |
Naphthyridine compounds as inhibitors of kras
|
|
US12030883B2
(en)
|
2021-09-21 |
2024-07-09 |
Incyte Corporation |
Hetero-tricyclic compounds as inhibitors of KRAS
|
|
WO2023051926A1
(en)
|
2021-09-30 |
2023-04-06 |
BioNTech SE |
Treatment involving non-immunogenic rna for antigen vaccination and pd-1 axis binding antagonists
|
|
US12030884B2
(en)
|
2021-10-01 |
2024-07-09 |
Incyte Corporation |
Pyrazoloquinoline KRAS inhibitors
|
|
WO2023057534A1
(en)
|
2021-10-06 |
2023-04-13 |
Genmab A/S |
Multispecific binding agents against pd-l1 and cd137 in combination
|
|
TW202333802A
(zh)
|
2021-10-11 |
2023-09-01 |
德商拜恩迪克公司 |
用於肺癌之治療性rna(二)
|
|
KR20240101561A
(ko)
|
2021-10-14 |
2024-07-02 |
인사이트 코포레이션 |
Kras의 저해제로서의 퀴놀린 화합물
|
|
WO2023083439A1
(en)
|
2021-11-09 |
2023-05-19 |
BioNTech SE |
Tlr7 agonist and combinations for cancer treatment
|
|
MX2024006113A
(es)
|
2021-11-22 |
2024-07-29 |
Incyte Corp |
Terapia de combinación que comprende un inhibidor del receptor del factor de crecimiento de fibroblastos (fgfr) y un inhibidor del sarcoma de rata de kirsten (kras).
|
|
TW202329937A
(zh)
|
2021-12-03 |
2023-08-01 |
美商英塞特公司 |
雙環胺ｃｋ１２抑制劑
|
|
US11976073B2
(en)
|
2021-12-10 |
2024-05-07 |
Incyte Corporation |
Bicyclic amines as CDK2 inhibitors
|
|
US12084453B2
(en)
|
2021-12-10 |
2024-09-10 |
Incyte Corporation |
Bicyclic amines as CDK12 inhibitors
|
|
CA3240558A1
(en)
|
2021-12-16 |
2023-06-22 |
Valerio Therapeutics |
New conjugated nucleic acid molecules and their uses
|
|
CR20240297A
(es)
|
2021-12-22 |
2024-09-18 |
Incyte Corp |
Sales y formas sólidas de un inhibidor de fgfr y procesos para su preparación
|
|
EP4469065A1
(en)
|
2022-01-28 |
2024-12-04 |
Iovance Biotherapeutics, Inc. |
Cytokine associated tumor infiltrating lymphocytes compositions and methods
|
|
JP2025512710A
(ja)
|
2022-03-07 |
2025-04-22 |
インサイト・コーポレイション |
Ｃｄｋ２阻害剤の固体形態、塩、ならびに調製プロセス
|
|
US20250206775A1
(en)
|
2022-03-18 |
2025-06-26 |
Bristol-Myers Squibb Company |
Methods of isolating polypeptides
|
|
WO2023214325A1
(en)
|
2022-05-05 |
2023-11-09 |
Novartis Ag |
Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
|
|
CA3253038A1
(en)
|
2022-05-12 |
2023-11-16 |
Genmab A/S |
LIAISON AGENTS CAPABLE OF BINDING TO CD27 IN POLYTHERAPY
|
|
IL317203A
(en)
|
2022-05-27 |
2025-01-01 |
Takeda Pharmaceuticals Co |
CD38-binding fusion protein dosage
|
|
AU2023281061A1
(en)
|
2022-06-02 |
2024-12-05 |
Bristol-Myers Squibb Company |
Antibody compositions and methods of use thereof
|
|
CN119998295A
(zh)
|
2022-06-08 |
2025-05-13 |
因赛特公司 |
作为dgk抑制剂的三环三唑并化合物
|
|
TW202413359A
(zh)
|
2022-06-22 |
2024-04-01 |
美商英塞特公司 |
雙環胺ｃｄｋ１２抑制劑
|
|
JP2025521543A
(ja)
|
2022-06-22 |
2025-07-10 |
ジュノー セラピューティクス インコーポレイテッド |
Ｃｄ１９標的ｃａｒ ｔ細胞のセカンドライン治療のための処置方法
|
|
US20240101557A1
(en)
|
2022-07-11 |
2024-03-28 |
Incyte Corporation |
Fused tricyclic compounds as inhibitors of kras g12v mutants
|
|
US12600722B2
(en)
|
2022-07-18 |
2026-04-14 |
Incyte Corporation |
Tetracyclic compounds as DGK inhibitors
|
|
US12600723B2
(en)
|
2022-07-18 |
2026-04-14 |
Incyte Corporation |
Tetracyclic compounds as DGK inhibitors
|
|
EP4565262A2
(en)
|
2022-08-05 |
2025-06-11 |
Juno Therapeutics, Inc. |
Chimeric antigen receptors specific for gprc5d and bcma
|
|
US20260151376A1
(en)
|
2022-10-20 |
2026-06-04 |
Institut National de la Santé et de la Recherche Médicale |
Combination therapy for the treatment of cancer
|
|
US20240217989A1
(en)
|
2022-11-18 |
2024-07-04 |
Incyte Corporation |
Heteroaryl Fluoroalkenes As DGK Inhibitors
|
|
CN120302979A
(zh)
|
2022-12-01 |
2025-07-11 |
生物技术公司 |
针对CD40和CD137的多特异性抗体与抗PD1 Ab和化学治疗的组合治疗
|
|
US20260207667A1
(en)
|
2022-12-13 |
2026-07-23 |
Juno Therapeutics, Inc. |
Chimeric antigen receptors specific for baff-r and cd19 and methods and uses thereof
|
|
JP2026501506A
(ja)
|
2022-12-14 |
2026-01-16 |
アステラス・ファーマ・ヨーロッパ・ベスローデン・フェンノートシャップ |
Ｃｌｄｎ１８．２及びｃｄ３に結合する二重特異性結合剤並びに免疫チェックポイント阻害剤を含む併用療法
|
|
TW202428575A
(zh)
|
2023-01-12 |
2024-07-16 |
美商英塞特公司 |
作為ｄｇｋ抑制劑之雜芳基氟代烯烴
|
|
US20260217828A1
(en)
|
2023-01-31 |
2026-07-30 |
University Of Rochester |
Immune checkpoint blockade therapy for treating staphylococcus aureus infections
|
|
EP4688160A1
(en)
|
2023-04-06 |
2026-02-11 |
Genmab A/S |
Multispecific binding agents against pd-l1 and cd137 for treating cancer
|
|
US20240390340A1
(en)
|
2023-04-18 |
2024-11-28 |
Incyte Corporation |
Pyrrolidine kras inhibitors
|
|
KR20260011682A
(ko)
|
2023-04-18 |
2026-01-23 |
인사이트 코포레이션 |
2-아자비사이클로[2.2.1]헵탄 kras 억제제
|
|
IL324457A
(en)
|
2023-05-12 |
2026-01-01 |
Genmab As |
Antibodies capable of binding to ox40, their variants and uses thereof
|
|
WO2024254245A1
(en)
|
2023-06-09 |
2024-12-12 |
Incyte Corporation |
Bicyclic amines as cdk2 inhibitors
|
|
CN121712571A
(zh)
|
2023-08-15 |
2026-03-20 |
百时美施贵宝公司 |
陶瓷羟基磷灰石色谱流通法
|
|
US20250066363A1
(en)
|
2023-08-24 |
2025-02-27 |
Incyte Corporation |
Bicyclic DGK Inhibitors
|
|
WO2025056180A1
(en)
|
2023-09-15 |
2025-03-20 |
BioNTech SE |
Methods of treatment using agents binding to epcam and cd137 in combination with pd-1 axis binding antagonists
|
|
WO2025068461A1
(en)
|
2023-09-29 |
2025-04-03 |
Negio Therapeutics |
Guanfacine derivatives and their use in treating cancer
|
|
WO2025068452A1
(en)
|
2023-09-29 |
2025-04-03 |
Negio Therapeutics |
Guanfacine derivatives and their use in treating cancer
|
|
US20250114346A1
(en)
|
2023-10-09 |
2025-04-10 |
Incyte Corporation |
Combination therapy using a kras g12d inhibitor and pd-1 inhibitor or pd-l1 inhibitor
|
|
TW202515903A
(zh)
|
2023-10-12 |
2025-04-16 |
瑞士商百濟神州瑞士有限責任公司 |
手術前後基於抗ｐｄ－１之治療
|
|
US20250163079A1
(en)
|
2023-11-01 |
2025-05-22 |
Incyte Corporation |
Kras inhibitors
|
|
CN122249464A
(zh)
|
2023-11-30 |
2026-06-19 |
金麦安博股份有限公司 |
在组合疗法中的能够结合ox40的抗体
|
|
TW202523667A
(zh)
|
2023-12-05 |
2025-06-16 |
美商英塞特公司 |
作為ｄｇｋ抑制劑之三環三唑并化合物
|
|
US20250186450A1
(en)
|
2023-12-06 |
2025-06-12 |
Incyte Corporation |
COMBINATION THERAPY COMPRISING DGK INHIBITORS and PD-1/PD-L1 INHIBITORS
|
|
AR134560A1
(es)
|
2023-12-08 |
2026-01-28 |
Astellas Pharma Inc |
Terapia de combinación que implica agentes de unión biespecíficos que se unen a cldn18.2 y cd3 y agentes que estabilizan o aumentan la expresión de cldn18.2
|
|
WO2025120866A1
(en)
|
2023-12-08 |
2025-06-12 |
Astellas Pharma Inc. |
Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
|
|
WO2025120867A1
(en)
|
2023-12-08 |
2025-06-12 |
Astellas Pharma Inc. |
Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies
|
|
WO2026033885A1
(en)
|
2024-08-08 |
2026-02-12 |
Astellas Pharma Inc. |
Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
|
|
WO2025129002A1
(en)
|
2023-12-13 |
2025-06-19 |
Incyte Corporation |
Bicyclooctane kras inhibitors
|
|
WO2025132831A1
(en)
|
2023-12-19 |
2025-06-26 |
Universite D'aix-Marseille |
N-heteroaryl derivatives and uses thereof for treating cancer
|
|
CN122459678A
(zh)
|
2023-12-29 |
2026-07-24 |
百时美施贵宝公司 |
KRAS抑制剂与Treg耗竭剂的组合疗法
|
|
WO2025153834A1
(en)
|
2024-01-19 |
2025-07-24 |
Institut National de la Santé et de la Recherche Médicale |
Methods of predicting the risk of recurrence and/or death of patients suffering from a hepatocellular carcinoma (hcc)
|
|
TW202545567A
(zh)
|
2024-01-30 |
2025-12-01 |
美商思進公司 |
抗ｐｄ－ｌ１抗體和抗體－藥物共軛體及彼等在治療癌症的用途
|
|
WO2025202213A1
(en)
|
2024-03-26 |
2025-10-02 |
Institut National de la Santé et de la Recherche Médicale |
Lipid nanoparticle loaded with antitumoral agent and functionnalized to target immosuppressive cells
|
|
WO2025219595A1
(en)
|
2024-04-19 |
2025-10-23 |
Biper Therapeutics |
Method for combination treatments using alkynylbenzenesulphonamides for cancer therapy
|
|
WO2025252857A1
(en)
|
2024-06-05 |
2025-12-11 |
Institut National de la Santé et de la Recherche Médicale |
Il-15 muteins with ph-dependent binding for il-15ralpha
|
|
WO2025252855A1
(en)
|
2024-06-05 |
2025-12-11 |
Institut National de la Santé et de la Recherche Médicale |
IL-15 MUTEINS WITH PH-DEPENDENT BINDING FOR IL-15Rbeta
|
|
WO2025262250A1
(en)
|
2024-06-20 |
2025-12-26 |
Negio Therapeutics |
Guanfacine derivatives and their uses
|
|
WO2026060143A1
(en)
|
2024-09-11 |
2026-03-19 |
Incyte Corporation |
Kras inhibitors
|
|
WO2026076207A1
(en)
|
2024-10-04 |
2026-04-09 |
Incyte Corporation |
Tricyclic heteroaryl compounds as inhibitors of tyk2 and/or jak1
|
|
US20260125391A1
(en)
|
2024-11-04 |
2026-05-07 |
Incyte Corporation |
Pyrimidine indoles as cdk4 inhibitors
|
|
WO2026107031A1
(en)
|
2024-11-13 |
2026-05-21 |
Incyte Corporation |
Kras inhibitors
|
|
WO2026136792A1
(en)
|
2024-12-20 |
2026-06-25 |
Nuvalent, Inc. |
Heteroaryl compounds as modulators of akt activity
|
|
US20260209246A1
(en)
|
2025-01-23 |
2026-07-23 |
Incyte Corporation |
Furanyl or thienyl pyrimidines as cdk4 inhibitors
|